EGFR and non-small cell lung carcinoma: Notably, an important recent single-arm phase II study showed that in EGFR-TKI-resistant NSCLC, the regime of ICI combined with chemotherapy could result in a favorable objective remission rate (ORR, 50%), PFS (7 months), and OS (23.5 months) (13).